FINWIRES · TerminalFinancial News · Live TerminalLIVE

HKG:1093

60 stories mentioning HKG:1093Updated just now

Every FINWIRES story that references HKG:1093, newest first.

What are analysts saying about HKG:1093?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on HKG:1093?

CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drug

CSPC Pharmaceutical Group (HKG:1093) said its SYS6010 drug has received Breakthrough Therapy Designation from China's National Medical Products Administration.The designation covers the treatment of recurrent or metastatic non-squamous non-small cell lung cancer with actionable genomic alteration-negative status in patients whose disease has progressed after prior immunotherapy and platinum-based chemotherapy, according to a Tuesday Hong Kong exchange filing.

CSPC Pharma's SYH9087 Injection Gets China Nod for Parkinson's Disease Trial

CSPC Pharmaceutical Group's (HKG:1093) SYH9087 injection obtained clinical trial approval from China's National Medical Products Administration.The indication for this clinical trial approval is Parkinson's disease, according to a Wednesday Hong Kong bourse filing.

CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug

CSPC Pharmaceutical Group's (HKG:1093) SYH9102 injection obtained clinical trial approval from China's National Medical Products Administration.The clinical indication is for patients with solid tumors, according to a Wednesday Hong Kong bourse filing.

CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials

CSPC Pharmaceutical Group's (HKG:1093) SYH2083 eye drops received approval from the National Medical Products Administration to begin clinical trials in China.The class 1 innovative drug is being developed for dry eye disease, according to a Tuesday Hong Kong bourse filing.

CSPC Pharma Begins Phase II Study of Influenza Drug in China

CSPC Pharmaceutical Group (HKG:1093) began a phase II clinical trial of SYH2085 tablets in China.The drug was developed by the company to treat uncomplicated influenza in adults, according to a Monday bourse filing.

CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China

CSPC Pharmaceutical Group's (HKG:1093) SYS6010 has been granted another Breakthrough Therapy Designation by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The designation is for the proposed indication of recurrent or metastatic head and neck squamous cell carcinoma in patients who have failed prior immunotherapy and platinum-based chemotherapy.

CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China

CSPC Pharmaceutical Group's (HKG:1093) SYS6010 was granted another Breakthrough Therapy Designation by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The designation is for the drug's proposed indication of recurrent or metastatic head and neck squamous cell carcinoma in patients who have failed prior immunotherapy and platinum-based chemotherapy.

CSPC Pharma Initiates Depression Drug Candidate Trial in China

CSPC Pharmaceutical Group (HKG:1093) officially began a phase 1 clinical trial of SYH2056 tablets for the treatment of depression.The trial in China will study the safety, tolerability, and pharmacokinetic profile of the product, as well as the food effect in healthy participants, according to a Tuesday filing with the Hong Kong bourse.

CSPC Pharma Begins Trial for Weight Management Drug in China

CSPC Pharmaceutical Group (HKG:1093) officially began a phase I clinical trial of the SYH2092 injection at the first center in China.The drug has been developed for weight management in adult patients with obesity.

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for the SYH2092 injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The product has the potential to bring significant clinical benefits for weight management in patients with obesity and improve glycaemic control in patients with type 2 diabetes mellitus.

CSPC Pharma's Colorectal Cancer Drug Candidate Gets Fast Track Designation by US FDA

CSPC Pharmaceutical Group's (HKG:1093) SYS6090 (JMT108) was granted Fast Track designation by the U.S. Food and Drug Administration (FDA).The designation is for the treatment of patients with metastatic colorectal cancer, according to a Wednesday Hong Kong bourse filing.

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

CSPC Pharmaceutical Group (HKG:1093) SYS6010 met the pre-specified primary endpoint of progression-free survival as reviewed by the Independent Data Monitoring Committee.The endpoint was reached in a phase III trial testing the product as a monotherapy versus platinum-based chemotherapy for non-small cell lung cancer, according to a Wednesday Hong Kong bourse filing.According to the results, the drug candidate's progression-free survival was significantly superior to existing treatment regimens, with high efficacy and favorable safety profile.

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

CSPC Pharmaceutical Group (HKG:1093) has an average rating of buy and mean price target of HK$12.33, according to analysts polled by FactSet.

Research25d ago

UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50

CSPC Pharmaceutical Group (HKG:1093) has an average rating of overweight and mean price target of HK$12.07, according to analysts polled by FactSet.

CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14%

CSPC Pharmaceutical Group (HKG:1093) reported an over 139% jump in attributable profit for the first half of 2026 to 6.09 billion yuan from 2.55 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.Earnings per share for the six months ended June 30 climbed to 0.5336 yuan from 0.2229 yuan in the prior-year period.Revenue of the pharma company jumped 40.1% year on year to 18.6 billion yuan from 13.3 billion yuan.The company declared an interim dividend of HK$0.18 per share, payable on Nov. 10 to shareholders of record on Oct. 26.Shares of the company jumped nearly 14% in recent trade.

CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China

CSPC Pharmaceutical Group (HKG:1093) said the new drug application for Anbenitamab in combination with its Docetaxel for Injection (Albumin-bound) was accepted by China's National Medical Products Administration.The drug, co-developed by unit Shanghai JMT-BIO Technology and Jiangsu Alphamab Oncology for the first-line treatment of advanced breast cancer, was also included in the priority review procedure.

CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus

CSPC Pharmaceutical (HKG:1093) said Phase 1 clinical trial of its SYS6063 CAR-T therapy for relapsed/refractory systemic lupus erythematosus has begun at its first clinical center in China, according to a Tuesday Hong Kong bourse filing.The trial is a multicentre, single-arm, open-label study involving dose escalation and expansion.It will assess the drug's safety, tolerability, efficacy, pharmacokinetics, and immunogenicity, with patient recruitment and screening underway.

CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA

CSPC Pharmaceutical's (HKG:1093) SYS6037 Injection obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.The mpox vaccine was co-developed by the company and the Institute of Microbiology, the Chinese Academy of Sciences, according to a Monday Hong Kong bourse filing.

CSPC Pharma Gets $10 Million Milestone Payment from AstraZeneca Under Research Deal

CSPC Pharmaceutical (HKG:1093) received a milestone payment of $10 million from AstraZeneca on Wednesday under a 2025 research collaboration agreement, according to a same-day Hong Kong bourse filing.The move was related to the exercise of a license option for one of the pre-clinical candidate programs under the contract, signifying that the relevant R&D work is progressing as planned.

CSPC Pharma, AstraZeneca Form JV to Build Biologics Manufacturing Facility in China

CSPC Pharmaceutical Group (HKG:1093) and AstraZeneca have agreed to establish a joint venture to build a new-generation biologics manufacturing facility in Shijiazhuang, China, as part of their strategic collaboration.Under the agreement, CSPC will hold a 51% stake in the JV, while AstraZeneca will own the remaining 49%. The two companies will jointly manage the construction and operations of the facility.The JV will initially focus on manufacturing and supplying agreed biologic drug substances for global markets, with potential to expand its product scope as capacity and demand grow. The agreement remains subject to customary closing conditions, including regulatory approvals.

Showing 1-20 of 60

Track with the FINWIRES app suite

Track HKG:1093 in your portfolio

Analyze HKG:1093 options with the wheel strategy

See market sentiment on HKG:1093